Hypoxia-autophagy axis induces VEGFA by peritoneal mesothelial cells to promote gastric cancer peritoneal metastasis through an integrin α5-fibronectin pathway.


Journal

Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647

Informations de publication

Date de publication:
20 Oct 2020
Historique:
received: 26 07 2020
accepted: 07 09 2020
entrez: 21 10 2020
pubmed: 22 10 2020
medline: 7 7 2021
Statut: epublish

Résumé

Peritoneal metastasis (PM) is an important pathological process in the progression of gastric cancer (GC). The metastatic potential of tumor and stromal cells is governed by hypoxia, which is a key molecular feature of the tumor microenvironment. Mesothelial cells also participate in this complex and dynamic process. However, the molecular mechanisms underlying the hypoxia-driven mesothelial-tumor interactions that promote peritoneal metastasis of GC remain unclear. We determined the hypoxic microenvironment in PM of nude mice by immunohistochemical analysis and screened VEGFA by human growth factor array kit. The crosstalk mediated by VEGFA between peritoneal mesothelial cells (PMCs) and GC cells was determined in GC cells incubated with conditioned medium prepared from hypoxia-treated PMCs. The association between VEGFR1 and integrin α5 and fibronectin in GC cells was enriched using Gene Set Enrichment Analysis and KEGG pathway enrichment analysis. In vitro and xenograft mouse models were used to evaluate the impact of VEGFA/VEGFR1 on gastric cancer peritoneal metastasis. Confocal microscopy and immunoprecipitation were performed to determine the effect of hypoxia-induced autophagy. Here we report that in the PMCs of the hypoxic microenvironment, SIRT1 is degraded via the autophagic lysosomal pathway, leading to increased acetylation of HIF-1α and secretion of VEGFA. Under hypoxic conditions, VEGFA derived from PMCs acts on VEGFR1 of GC cells, resulting in p-ERK/p-JNK pathway activation, increased integrin α5 and fibronectin expression, and promotion of PM. Our findings have elucidated the mechanisms by which PMCs promote PM in GC in hypoxic environments. This study also provides a theoretical basis for considering autophagic pathways or VEGFA as potential therapeutic targets to treat PM in GC.

Sections du résumé

BACKGROUND BACKGROUND
Peritoneal metastasis (PM) is an important pathological process in the progression of gastric cancer (GC). The metastatic potential of tumor and stromal cells is governed by hypoxia, which is a key molecular feature of the tumor microenvironment. Mesothelial cells also participate in this complex and dynamic process. However, the molecular mechanisms underlying the hypoxia-driven mesothelial-tumor interactions that promote peritoneal metastasis of GC remain unclear.
METHODS METHODS
We determined the hypoxic microenvironment in PM of nude mice by immunohistochemical analysis and screened VEGFA by human growth factor array kit. The crosstalk mediated by VEGFA between peritoneal mesothelial cells (PMCs) and GC cells was determined in GC cells incubated with conditioned medium prepared from hypoxia-treated PMCs. The association between VEGFR1 and integrin α5 and fibronectin in GC cells was enriched using Gene Set Enrichment Analysis and KEGG pathway enrichment analysis. In vitro and xenograft mouse models were used to evaluate the impact of VEGFA/VEGFR1 on gastric cancer peritoneal metastasis. Confocal microscopy and immunoprecipitation were performed to determine the effect of hypoxia-induced autophagy.
RESULTS RESULTS
Here we report that in the PMCs of the hypoxic microenvironment, SIRT1 is degraded via the autophagic lysosomal pathway, leading to increased acetylation of HIF-1α and secretion of VEGFA. Under hypoxic conditions, VEGFA derived from PMCs acts on VEGFR1 of GC cells, resulting in p-ERK/p-JNK pathway activation, increased integrin α5 and fibronectin expression, and promotion of PM.
CONCLUSIONS CONCLUSIONS
Our findings have elucidated the mechanisms by which PMCs promote PM in GC in hypoxic environments. This study also provides a theoretical basis for considering autophagic pathways or VEGFA as potential therapeutic targets to treat PM in GC.

Identifiants

pubmed: 33081836
doi: 10.1186/s13046-020-01703-x
pii: 10.1186/s13046-020-01703-x
pmc: PMC7576728
doi:

Substances chimiques

Biomarkers, Tumor 0
FN1 protein, human 0
Fibronectins 0
Integrin alpha5 0
VEGFA protein, human 0
Vascular Endothelial Growth Factor A 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

221

Subventions

Organisme : the National Key R&D Program of China
ID : 2016YFC1302400
Organisme : The Ministry of education innovation team development plan
ID : IRT_17R107&IRT13101
Organisme : Key project of the National Natural Science Foundation
ID : 81130042, 31171323, 81770001
Organisme : National Natural Science Foundation of China
ID : NO.8197103748
Organisme : National Natural Science Foundation of China
ID : 81803092
Organisme : National Natural Science Foundation of China
ID : NO. 81702738
Organisme : The Key Research and Development Program of Liaoning Province
ID : 2018225060
Organisme : Science and Technology Plan Project of Shenyang city
ID : 19-112-4-099

Références

Int J Cancer. 2014 Feb 1;134(3):622-8
pubmed: 23832847
Oncologist. 2010;15(6):577-83
pubmed: 20484123
Mol Cell. 2007 Oct 26;28(2):277-90
pubmed: 17964266
Clin Cancer Res. 2006 Sep 1;12(17):5018-22
pubmed: 16951216
Front Oncol. 2020 Apr 23;10:513
pubmed: 32391262
Nat Rev Cancer. 2018 Sep;18(9):533-548
pubmed: 30002479
Mol Cell. 2012 May 25;46(4):484-94
pubmed: 22542455
Gastric Cancer. 2005;8(3):155-63
pubmed: 16086118
Cancer Lett. 2014 Dec 28;355(2):310-5
pubmed: 25301450
Circ Res. 2018 Mar 30;122(7):945-957
pubmed: 29467198
J Exp Med. 2010 Dec 20;207(13):2855-68
pubmed: 21098094
Cancer Med. 2019 Apr;8(4):1731-1743
pubmed: 30791228
Exp Cell Res. 2018 Jul 15;368(2):184-193
pubmed: 29709516
Int J Oncol. 1996 Apr;8(4):795-802
pubmed: 21544429
Methods Mol Biol. 2008;445:77-88
pubmed: 18425443
Nat Rev Mol Cell Biol. 2009 Jul;10(7):458-67
pubmed: 19491929
Cancer Res. 2019 May 1;79(9):2271-2284
pubmed: 30862717
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13421-6
pubmed: 18755897
Nat Cell Biol. 2007 Nov;9(11):1253-62
pubmed: 17934453
Cell Res. 2014 Jan;24(1):24-41
pubmed: 24366339
Cell Death Dis. 2018 Nov 19;9(12):1152
pubmed: 30455420
Cancer Res. 1986 Jan;46(1):1-7
pubmed: 2998604
Int J Biol Sci. 2019 Jan 1;15(3):507-521
pubmed: 30745838
PLoS One. 2014 May 14;9(5):e97271
pubmed: 24827582
J Natl Cancer Inst. 1998 Mar 18;90(6):447-54
pubmed: 9521169
World J Crit Care Med. 2013 Nov 04;2(4):48-55
pubmed: 24701416
Cancer Res. 2007 Mar 15;67(6):2729-35
pubmed: 17363594
Angiogenesis. 2006;9(4):225-30; discussion 231
pubmed: 17109193
Nat Cell Biol. 2010 Sep;12(9):814-22
pubmed: 20811353
Clin Cancer Res. 2000 Feb;6(2):622-30
pubmed: 10690548
Oncogene. 2000 Nov 20;19(49):5598-605
pubmed: 11114740
Aging Cell. 2019 Apr;18(2):e12904
pubmed: 30614190
J Cell Mol Med. 2018 Jan;22(1):89-100
pubmed: 28799229
PLoS One. 2013 Sep 04;8(9):e73229
pubmed: 24023838
J Exp Med. 2012 Mar 12;209(3):507-20
pubmed: 22393126
Science. 2004 Nov 5;306(5698):1037-40
pubmed: 15528445
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Lancet. 2016 Nov 26;388(10060):2654-2664
pubmed: 27156933
Mol Cell. 2010 Jun 25;38(6):864-78
pubmed: 20620956
Lab Invest. 2019 Sep;99(9):1266-1274
pubmed: 30988371
Gene Ther. 2000 Jun;7(12):1027-33
pubmed: 10871751
J Surg Oncol. 2011 Nov 1;104(6):692-8
pubmed: 21713780

Auteurs

Xiaoxun Wang (X)

Institute of Translational Medicine, Key Laboratory of Cell Biology of Ministry of Public Health, Key Laboratory of Medical Cell Biology of Ministry of Education, Liaoning Province Collaborative Innovation Center of Aging Related Disease Diagnosis and Treatment and Prevention, China Medical University, Shenyang, 110001, Liaoning, China.

Xiaofang Che (X)

Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.
Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.

Yang Yu (Y)

Institute of Translational Medicine, Key Laboratory of Cell Biology of Ministry of Public Health, Key Laboratory of Medical Cell Biology of Ministry of Education, Liaoning Province Collaborative Innovation Center of Aging Related Disease Diagnosis and Treatment and Prevention, China Medical University, Shenyang, 110001, Liaoning, China.

Yu Cheng (Y)

Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.
Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.

Ming Bai (M)

Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.
Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.

Zichang Yang (Z)

Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.
Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.

Qiqiang Guo (Q)

Institute of Translational Medicine, Key Laboratory of Cell Biology of Ministry of Public Health, Key Laboratory of Medical Cell Biology of Ministry of Education, Liaoning Province Collaborative Innovation Center of Aging Related Disease Diagnosis and Treatment and Prevention, China Medical University, Shenyang, 110001, Liaoning, China.

Xiaochen Xie (X)

Department of Endocrinology and Metabolism, Institute of Endocrinology, Liaoning Provincial Key Laboratory of Endocrine Diseases, The First Affiliated Hospital of China Medical University, China Medical University, Shenyang, 110001, China.

Danni Li (D)

Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.
Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.

Min Guo (M)

Institute of Translational Medicine, Key Laboratory of Cell Biology of Ministry of Public Health, Key Laboratory of Medical Cell Biology of Ministry of Education, Liaoning Province Collaborative Innovation Center of Aging Related Disease Diagnosis and Treatment and Prevention, China Medical University, Shenyang, 110001, Liaoning, China.

Kezuo Hou (K)

Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.
Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.

Wendong Guo (W)

Institute of Translational Medicine, Key Laboratory of Cell Biology of Ministry of Public Health, Key Laboratory of Medical Cell Biology of Ministry of Education, Liaoning Province Collaborative Innovation Center of Aging Related Disease Diagnosis and Treatment and Prevention, China Medical University, Shenyang, 110001, Liaoning, China.

Xiujuan Qu (X)

Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China. xiujuanqu@yahoo.com.
Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China. xiujuanqu@yahoo.com.

Liu Cao (L)

Institute of Translational Medicine, Key Laboratory of Cell Biology of Ministry of Public Health, Key Laboratory of Medical Cell Biology of Ministry of Education, Liaoning Province Collaborative Innovation Center of Aging Related Disease Diagnosis and Treatment and Prevention, China Medical University, Shenyang, 110001, Liaoning, China. lcao@cmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH